Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The internal proteins of Influenza A virus, including M1, M2, NP, PB1, PB2, PA, NEP/NS2, and PB1-F2, are essential for the virus's structure, replication, and pathogenesis. Due to their relatively high conservation compared to surface antigens, they are attractive targets for universal influenza vaccine development. Expression via single-replication vectors offers a safer method for studying immune responses and developing vaccine candidates.
Varied; M2 inhibitors block ion channel activity, preventing uncoating. Other internal proteins are targets for vaccine development aiming to elicit broader immune responses.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A Virus Internal Proteins (N/A).